key: cord-0744493-kp2o0rk2
authors: Ciuffreda, Laura; Salazar, José M. Lorenzo; Alcoba-Florez, Julia; Rodriguez-Pérez, Héctor; Gil-Campesino, Helena; Íñigo-Campos, Antonio; de Artola, Diego García-Martínez; Valenzuela-Fernández, Agustín; Hayek-Peraza, Marcelino; Rojo-Alba, Susana; Alvarez-Argüelles, Marta Elena; Díez-Gil, Oscar; González-Montelongo, Rafaela; Flores, Carlos
title: Longitudinal study of a SARS-CoV-2 infection in an immunocompromised patient with X-linked agammaglobulinemia
date: 2021-07-28
journal: J Infect
DOI: 10.1016/j.jinf.2021.07.028
sha: 448f327a58f906ab408b52cfc7788da21784128f
doc_id: 744493
cord_uid: kp2o0rk2

nan

In this journal, Walsh and colleagues (1) recently reviewed the evidence supporting that neutralizing activity of the hyperimmune serum used. Lastly, the emergence of mutations distinctive of currently circulating SARS-CoV-2 variants of concern (VOCs) support the hypothesis for long-term viral shedding in immunocompromised patients as one possible mechanism for the emergence of VOCs.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

This work was supported by Cabildo Insular de Tenerife [grants CGIEU0000219140 and "Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19"]; the agreement with Instituto The funders had no role in the study design, collection, analysis and interpretation of data, in the writing of the manuscript or in the decision to submit the manuscript for publication. 

The duration of infectiousness of individuals infected with SARS-CoV-2

SARS-CoV-2 variants, spike mutations and immune escape

Spreading of a new SARS-CoV-2 N501Y spike variant in a new lineage

Local emergence and decline of a SARS-CoV-2 variant with mutations L452R and N501Y in the spike protein

Vaccine-escape and fast-growing mutations in the United Kingdom, the United States

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

RT-qPCR cycle threshold (Ct) are shown for collected nasopharyngeal swab (NP, circle) and bronchoalveolar (BAL, triangle) samples, with sequenced samples highlighted in blue. Vertical bars represent the accumulated number of mutations in the sequenced genome compared to the consensus viral sequence obtained from the first NP sample (day 9). † At day 50, a BAL sample was shown to have actively replicating SARS-CoV-2 viruses. B) Graphical representation of SARS-CoV-2 whole-genome consensus sequences with synonymous (blue asterisks) and nonsynonymous mutations (orange asterisks) identified as compared to the Wuhan-Hu-1 reference sequence (NC_045512.2). Only non-synonymous mutations are identified with the amino acid changes in the figure

We deeply acknowledge the University Hospital Nuestra Señora de Candelaria (HUNSC) and the